Skip to main content

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more

A new orally administered macrocylic antibiotic has been approved by the FDA for the treatment of Clostridium difficile infection. Fidaxomicin is a fermentation product of Dactylosporangium aurantiacum and is marketed by Optimer Pharmaceuticals, Inc., as Dificid.

Fidaxomicin Tablets (Dificid™)